Read by QxMD icon Read

Tumori | Page 2

Rosa Falcone, Adriana Romiti, Marco Filetti, Michela Roberto, Riccardo Righini, Andrea Botticelli, Emanuela Pilozzi, Michele Ghidini, Claudio Pizzo, Federica Mazzuca, Paolo Marchetti
BACKGROUND: Because of a lack of large-scale prospective studies there is no clear indication about the management of patients with small bowel adenocarcinoma (SBA). This study evaluated clinical outcome of patients diagnosed with SBA at our institution. METHODS: Clinicopathologic features, treatments, and clinical outcome of patients diagnosed with SBA between 2006 and 2017 were retrospectively analyzed. Median time of survival was calculated and compared using the log-rank test...
April 1, 2019: Tumori
Emre Akar, Mehmet Haluk Yücel, Tunahan Şahin, Deniz Tural
BACKGROUND: Cytotoxic and immunosuppressive therapies for cancer treatment may allow hepatitis reactivation. Hepatitis due to viral hepatitis reactivation is detected in 14%-25% of hepatitis B surface antigen (HBsAg)-positive cancer patients undergoing anticancer treatments. Drug toxicity may be confused with hepatitis reactivation, which may cause a delay in diagnosis. CASE REPORT: A 60-year-old man with metastatic renal cell carcinoma was treated with sunitinib...
April 1, 2019: Tumori
Di Wang, Yang Luo, Di Shen, Lin Yang, Hui-Ying Liu, Yi-Qun Che
BACKGROUND: Bone marrow metastasis occurs in lung adenocarcinoma patients with a poor prognosis due to the late course and lack of definitive treatments, although reports on this are limited. This study analyzed the clinical manifestation, laboratory examination, treatment, and prognosis of patients with lung adenocarcinoma with bone marrow metastasis. METHODS: All patients were confirmed to have bone marrow infiltration by bone marrow aspiration. The clinical data of 12 patients with lung adenocarcinoma with bone marrow metastasis were analyzed retrospectively...
April 1, 2019: Tumori
Carlotta Buzzoni, Emanuele Crocetti, Stefano Guzzinati, Luigino Dal Maso, Silvia Francisci
OBJECTIVE: To evaluate short-term (2003-2014) cancer incidence and mortality trends in Italy. METHODS: Italian Cancer Registries data, available in the AIRTUM database, from 17 out of 20 regions were used. The number of incident cases and deaths were estimated for those registries and those years with incomplete information. Age-standardized rates, overall and stratified by geographic area, region, sex, cancer site, and major age group, were computed. Time trends were expressed as annual percent change of rates...
April 2019: Tumori
Chiara Panato, Diego Serraino, Emilia De Santis, Ornella Forgiarini, Tiziana Angelin, Ettore Bidoli, Loris Zanier, Stefania Del Zotto, Salvatore Vaccarella, Silvia Franceschi, Luigino Dal Maso
BACKGROUND: Incidence rates of thyroid cancer (TC) increased in the last decades worldwide. This study aimed to describe TC incidence in the Friuli Venezia Giulia (FVG) region, to estimate the quota of overdiagnosis, and to investigate the impact of surgery on long-term survival after TC diagnosis. METHODS: TC cases reported to the FVG population-based cancer registry during 2002-2013, aged <85 years, were included. Age standardized rates (ASR) on the European population were computed, while proportion of TC overdiagnosis was estimated in comparison with expected age-specific incidence rates from published time series...
March 28, 2019: Tumori
Domenica Lorusso, Ilaria Sabatucci, Giuseppa Maltese, Stefano Lepori, Elisa Tripodi, Giorgio Bogani, Francesco Raspagliesi
The vast majority of ovarian cancer relapses on front-line therapy and the optimal treatment of recurrent ovarian cancer remains controversial. This review is based on the relevant published literature indexed in PubMed on pegylated liposomal doxorubicin (PLD), either alone or in combination with other drugs, as one option in relapsed disease. PLD showed an improved pharmacokinetic profile, with a slower plasma clearance and a longer circulation time, compared to other conventional doxorubicin formulations...
March 28, 2019: Tumori
Manuel Zorzi, Luigino Dal Maso, Silvia Francisci, Carlotta Buzzoni, Massimo Rugge, Stefano Guzzinati
OBJECTIVE: To evaluate the trends of colorectal cancer (CRC) incidence and mortality rates from 2003 to 2014 in Italy by age groups and regions. METHODS: We used the data of 48 cancer registries from 17 Italian regions to estimate standardized incidence and mortality rates overall and by sex, age groups (<50, 50-69, 70+ years), and geographic area (northwest, northeast, center, south, and islands). Time trends were expressed as annual percent change in rates (APC) with 95% confidence intervals (95% CI)...
March 27, 2019: Tumori
Gunsu Kimyon Comert, Osman Turkmen, Cigdem Guler Mesci, Alper Karalok, Ozge Sever, Selcan Sinaci, Nurettin Boran, Derman Basaran, Taner Turan
OBJECTIVE: To evaluate the factors predicting oncologic outcomes in low-grade ovarian serous carcinoma (LGOSC). METHODS: Seventy patients with LGOSC were included in the study. According to the residual disease present at the end of the initial cytoreductive surgery (CRS), surgical outcomes are defined as follows: maximal CRS for absence of macroscopic residual tumors, optimal CRS for macroscopic residual tumors with diameters ranging from 0.1 to ⩽1 cm diameter, and suboptimal CRS for macroscopic residual tumors measuring >1 cm in diameter...
March 27, 2019: Tumori
Eliana La Rocca, Vanessa Lici, Tommaso Giandini, Francesca Bonfantini, Sarah Frasca, Michela Dispinzieri, Massimiliano Gennaro, S Serena Di Cosimo, Laura Lozza, Emanuele Pignoli, Riccardo Valdagni, Maria Carmen De Santis
PURPOSE: To examine interobserver variability between the radiation oncologist (RTO) and the radiation therapist (RTT) in delineating the tumor bed (TB) in early breast cancer (BC). METHODS: We retrospectively analyzed patients who received a radiotherapy boost to the TB. In a first group, the clinical target volume (CTV) for the boost was the surgical bed, defined by using surgical clips. In a second group, the CTV was defined by identifying a seroma cavity or a metallic find on the scar...
March 27, 2019: Tumori
Federica Grosso, Alessandro Croce, Roberta Libener, Narciso Mariani, Massimo Pastormerlo, Antonio Maconi, Caterina Rinaudo
PURPOSE: To assess whether asbestos fibers may be observed in liver tissue of patients with cholangiocarcinoma (CC) with environmental or working asbestos exposure. METHODS: Detection of fibers was performed directly on histologic sections of liver from 7 patients with CC using optical microscope and variable pressure scanning electron microscopy equipped with energy-dispersive spectroscopy (VP-SEM/EDS). All patients were from Casale Monferrato, Italy, a highly asbestos-polluted town...
March 27, 2019: Tumori
Lorenzo Livi, Beatrice Detti, Giulio Francolini, Francesca Terziani, Luca Triggiani, Rolando M D'Angelillo, Gianluca Ingrosso
Prostate cancer is the second most frequent cancer worldwide, with a very high rate of progression despite treatment. The most aggressive form of the disease is known as castration-resistant prostate cancer, which carries a poor prognosis. We reviewed available literature regarding the combination of abiraterone acetate antihormonal drug and ablative radiation therapy for the treatment of metastatic castration-resistant prostate cancer. This dual treatment may enhance the effects of second-line hormonal therapy, as radiotherapy renders cancer cells more prone to immune-mediated cytotoxicity...
March 25, 2019: Tumori
Byoung Soo Kwon, Ji Hyun Park, Seulgi Kim, Sojung Park, Wonjun Ji, Woo Sung Kim, Jae Cheol Lee, Yu Rang Park, Chang-Min Choi
BACKGROUND: This study aimed to estimate therapeutic effects of first-generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) in real-world practice, by analyzing survival outcomes in an unselected, Korean female population with advanced lung cancer based on the National Health Insurance Service database. METHODS: We identified women with newly diagnosed advanced lung cancer from January 2004 to December 2013. For progression-free survival (PFS) and overall survival (OS) analyses, patients were defined into the following subgroups: group A, treated with first-generation EGFR-TKI ⩾6 months; group B, treated with EGFR-TKIs <6 months but at least >1 month; and group C, treated with cytotoxic chemotherapy as follows: monotherapy or combination therapy with gemcitabine or pemetrexed; or monotherapy with docetaxel, paclitaxel, or vinorelbine...
March 25, 2019: Tumori
Laura Botta, Gemma Gatta, Annalisa Trama, Riccardo Capocaccia
BACKGROUND: The proportion of patients cured of cancer is usually estimated with cure models assuming they have the same death risk as the general population. These patients, even when cured, often maintain an extra death risk compared to the overall population. Our aims were to estimate this extra risk, and to take it into account in estimating cure proportions and relative survival (RS). METHODS: We used RS mixture model with an additional parameter expressing the extra noncancer death risk of patients, assumed constant with age...
March 25, 2019: Tumori
Juan A Muñoz-Largacha, Sowmya R Rao, Laurence H Brinckerhoff, Benedict D Daly, Hiran C Fernando, Virginia R Litle, Kei Suzuki
OBJECTIVE: To determine if induction chemotherapy with concurrent high-dose radiation followed by resection is associated with improved survival in patients with nonsuperior sulcus lung cancer with chest wall invasion. METHODS: We performed a retrospective review of clinical T3 (chest wall invasion) N0/N1 patients with non-small cell lung cancer who underwent surgical resection between January 1, 1992, and January 31, 2017. Exclusion criteria included superior sulcus tumors and resection performed for palliation/recurrence...
March 25, 2019: Tumori
Roberto Lisi, Gessica Abate, Pasqualina D'Urso, Maria Teresa Martinetti, Benedetta Siniscalchi, Francesco Marampon, Nadia Bulzonetti, Vincenzo Tombolini
BACKGROUND: Inflammatory myofibroblastic tumor (IMT) is a rare benign cancer that can express a more aggressive phenotype related to the genetic mutation of the anaplastic lymphoma kinase receptor (ALK). Involvement of trachea is extremely rare and due to the clinical and radiologic nonspecificity, the definitive diagnosis is based on the histologic evaluation of tissue specimens. Total surgical excision is curative and chemotherapy or radiotherapy has been employed in the treatment of unresectable tumors or as adjuvant therapies...
March 22, 2019: Tumori
Giuseppe Boni, Fabio Monari
No abstract text is available yet for this article.
March 14, 2019: Tumori
Sara Lonardi, Guglielmo Nasti, Daniele Fagnani, Donatello Gemma, Libero Ciuffreda, Cristina Granetto, Sara Lucchesi, Alberto Ballestrero, Maria Biglietto, Ilaria Proserpio, Francesca Bergamo, Emanuela Proietti, Giuseppe Tonini
AIMS: BEAWARE investigated the pattern of first-line bevacizumab early interruption in the Italian real-world setting of metastatic colorectal cancer. METHODS: A total of 386 patients were followed for 15 months after first-line chemotherapy + bevacizumab start. The rate of bevacizumab interruption for progression or adverse drug reactions (ADRs) constituted the primary endpoint. RESULTS: A total of 78.2% of patients interrupted bevacizumab: 56...
March 11, 2019: Tumori
Laurien De Roeck, Sandra Nuyts
INTRODUCTION: The most important long-term effect of radiotherapy is induction of secondary cancers. A rare radiation-induced tumor is a squamous cell carcinoma of the external auditory canal. Case reports have been described in Asian patients after radiotherapy for nasopharyngeal cancer. CASE DESCRIPTION: We describe an unusual case report of a 53-year-old Caucasian man who developed squamous cell carcinomas of the right and left external auditory canal, respectively 29 and 30 years after radiotherapy for a pituitary adenoma...
February 26, 2019: Tumori
Michele Fiore, Pasquale Trecca, Giuseppe Perrone, Michelina Amato, Daniela Righi, Lucio Trodella, Rolando M D'Angelillo, Sara Ramella
INTRODUCTION: Targeted therapies against epidermal growth factor receptor (EGFR) have revolutionized the treatment of a subset of lung adenocarcinomas that have EGFR-activating mutations; however, all patients treated with EGFR tyrosine kinase inhibitors (TKIs) ultimately develop resistance. Histologic transformation of EGFR-mutant adenocarcinoma to small cell lung cancer (SCLC) is a resistance mechanism rarely reported in the literature. CASE PRESENTATION: We describe the case of a woman with metastatic lung cancer adenocarcinoma with mutated EGFR with an initial response to gefitinib and radiation therapy, who progressed after 18 months due to the development of a resistance mechanism...
February 24, 2019: Tumori
Antonio Mastroianni, Rossella Panella, Daniele Morelli
PURPOSE: The integration of expertise between oncologist and clinical biochemist for the monitoring and diagnosis of plasma cell dyscrasia is crucial. In some cases, medical laboratory scientists can provide an original contribution using the appropriate techniques to arrive at a diagnosis. METHODS: We report a case of 67-year-old woman who was admitted to our hospital for bone pain. Imaging studies showed multiple diffuse bone lytic lesions, and a laboratory screen revealed anemia and altered creatinemia; serum capillary zone electrophoresis confirmed a monoclonal peak in the γ-zone that had been known since 2011, typed as immunoglobulin G kappa by immunosubtraction electrophoresis...
February 24, 2019: Tumori
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"